Identification

Name
Insulin Aspart
Accession Number
DB01306
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Hormones / Insulins
Description

Insulin aspart is a recombinant, biosynthetic, fast-acting insulin analogue. It has a single amino acid substitution at position B28 where proline is replaced with aspartic acid. This substitution decreases its propensity to form hexamers and gives it a higher rate of absorption following subcutaneous administration compared to native insulin. Insulin aspart is produced in a genetically modified strain of Saccharomyces cerevisiae and harvested from a bioreactor.

Protein structure
Db01306
Protein chemical formula
C256H381N65O79S6
Protein average weight
5825.8 Da
Sequences
>A chain
GIVEQCCTSICSLYQLENYCN
>B chain
FVNQHLCGSHLVEALYLVCGERGFFYTDKT
Download FASTA Format
Synonyms
  • Aspart
  • Aspart Insulin
  • B28-Aspart-Insulin
  • INA-X14
  • Insulin aspart protamine recombinant
  • Insulin aspart recombinant
  • Insulin X14
  • Insulin, Asp(B28)
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FiaspSolution100 unitSubcutaneousNovo Nordisk2017-03-03Not applicableCanada
FiaspInjection, solution100 [iU]/mLSubcutaneousNovo Nordisk2017-10-20Not applicableUs
FiaspSolution100 unitSubcutaneousNovo Nordisk2017-03-03Not applicableCanada
FiaspInjection, solution100 [iU]/mLSubcutaneousNovo Nordisk2017-10-20Not applicableUs
FiaspSolution100 unitSubcutaneousNovo Nordisk2017-03-03Not applicableCanada
NovoLogInjection, solution100 [iU]/mLIntravenous; SubcutaneousTYA Pharmaceuticals2001-08-27Not applicableUs
NovoLogInjection, solution100 [iU]/mLIntravenous; SubcutaneousA S Medication Solutions2001-08-272017-06-20Us
NovologInjection, solution100 [iU]/mLIntravenous; SubcutaneousNovo Nordisk2001-08-27Not applicableUs
NovologInjection, solution100 [iU]/mLIntravenous; SubcutaneousNovo Nordisk2001-08-27Not applicableUs
NovoLogInjection, solution100 [iU]/mLIntravenous; SubcutaneousDispensing Solutions, Inc.2003-01-22Not applicableUs
International/Other Brands
Novolog FlexPen (Novo Nordisk) / Novolog Penfill (Novo Nordisk) / NovoRapid Penfill (Novo Nordisk)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
RyzodegInsulin Aspart (1.05 mg/ml) + Insulin Degludec (2.56 mg/ml)Injection, solutionSubcutaneousNovo Nordisk2013-01-21Not applicableEu
RyzodegInsulin Aspart (1.05 mg/ml) + Insulin Degludec (2.56 mg/ml)Injection, solutionSubcutaneousNovo Nordisk2013-01-21Not applicableEu
RyzodegInsulin Aspart (1.05 mg/ml) + Insulin Degludec (2.56 mg/ml)Injection, solutionSubcutaneousNovo Nordisk2013-01-21Not applicableEu
RyzodegInsulin Aspart (1.05 mg/ml) + Insulin Degludec (2.56 mg/ml)Injection, solutionSubcutaneousNovo Nordisk2013-01-21Not applicableEu
RyzodegInsulin Aspart (1.05 mg/ml) + Insulin Degludec (2.56 mg/ml)Injection, solutionSubcutaneousNovo Nordisk2013-01-21Not applicableEu
RyzodegInsulin Aspart (1.05 mg/ml) + Insulin Degludec (2.56 mg/ml)Injection, solutionSubcutaneousNovo Nordisk2013-01-21Not applicableEu
RyzodegInsulin Aspart (1.05 mg/ml) + Insulin Degludec (2.56 mg/ml)Injection, solutionSubcutaneousNovo Nordisk2013-01-21Not applicableEu
Categories
UNII
D933668QVX
CAS number
116094-23-6

Pharmacology

Indication

For the treatment of Type 1 or 2 diabetes mellitus. Should normally be used in conjunction with an intermediate or long-acting insulin.

Structured Indications
Pharmacodynamics

Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, a basal level of insulin is supplemented with insulin spikes following meals. Postprandial insulin spikes are responsible for the metabolic changes that occur as the body transitions from a postabsorptive to absorptive state. Insulin promotes cellular uptake of glucose, particularly in muscle and adipose tissues, promotes energy storage via glycogenesis, opposes catabolism of energy stores, increases DNA replication and protein synthesis by stimulating amino acid uptake by liver, muscle and adipose tissue, and modifies the activity of numerous enzymes involved in glycogen synthesis and glycolysis. Insulin also promotes growth and is required for the actions of growth hormone (e.g. protein synthesis, cell division, DNA synthesis). Insulin aspart is a rapid-acting insulin analogue used to mimic postprandial insulin spikes in diabetic individuals. The onset of action of insulin aspart is 10-15 minutes. Its activity peaks 60-90 minutes following subcutaneous injection and its duration of action is 4-5 hours.

Mechanism of action

Insulin aspart binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the proline residue at B28 with aspartic acid reduces the tendency to form hexamers and results in a faster rate of absorption and onset of action and shorter duration of action.

TargetActionsOrganism
AInsulin receptor
agonist
Human
Absorption

Rapidly absorbed following subcutaneous administration (more so than regular human insulin). Furthermore, insulin aspart has a faster absorption, a faster onset of action, and a shorter duration of action than regular human insulin after subcutaneous injection. It takes 40 - 50 minutes to reach maximum concentration. When a dose of 0.15 U/kg body weight was injected in type 1 diabetes patients, the mean maximum concentration (Cmax) was 82 mU/L. The site of injection has no impact on extent or speed of absorption.

Volume of distribution
Not Available
Protein binding

<10% bound to plasma proteins.

Metabolism
Not Available
Route of elimination
Not Available
Half life

81 minutes (following subcutaneous administration in healthy subjects).

Clearance
  • 1.2 L/h/kg [healthy Caucasian male], excreted in the urine
Toxicity

Inappropriately high dosages relative to food intake and/or energy expenditure may result in severe and sometimes prolonged and life-threatening hypoglycemia. Neurogenic (autonomic) signs and symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea and tingling. Neuroglycopenic signs and symptoms of hypoglycemia include difficulty concentrating, lethargy/weakness, confusion, drowsiness, vision changes, difficulty speaking, headache, and dizziness. Mild hypoglycemia is characterized by the presence of autonomic symptoms. Moderate hypoglycemia is characterized by the presence of autonomic and neuroglycopenic symptoms. Individuals may become unconscious in severe cases of hypoglycemia.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedione2,4-thiazolidinedione may increase the hypoglycemic activities of Insulin Aspart.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Insulin Aspart.Experimental
AcarboseAcarbose may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Insulin Aspart.Investigational, Withdrawn
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Insulin Aspart.Approved, Vet Approved
AICA ribonucleotideAICA ribonucleotide may increase the hypoglycemic activities of Insulin Aspart.Experimental, Investigational
AlaproclateAlaproclate may increase the hypoglycemic activities of Insulin Aspart.Experimental
AllicinAllicin may increase the hypoglycemic activities of Insulin Aspart.Investigational
AlogliptinAlogliptin may increase the hypoglycemic activities of Insulin Aspart.Approved
AloxiprinAloxiprin may increase the hypoglycemic activities of Insulin Aspart.Experimental
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Insulin Aspart.Approved
AmphetamineAmphetamine may increase the hypoglycemic activities of Insulin Aspart.Approved, Illicit
AripiprazoleThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Aripiprazole.Approved, Investigational
Arsenic trioxideThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Asenapine.Approved
AtazanavirThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Atazanavir.Approved, Investigational
BalaglitazoneBalaglitazone may increase the hypoglycemic activities of Insulin Aspart.Investigational
BalsalazideBalsalazide may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
Bempedoic acidBempedoic acid may increase the hypoglycemic activities of Insulin Aspart.Investigational
BendroflumethiazideThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypoglycemic activities of Insulin Aspart.Withdrawn
BetamethasoneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BrexpiprazoleThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Brexpiprazole.Approved
BrofaromineBrofaromine may increase the hypoglycemic activities of Insulin Aspart.Experimental
BuforminBuformin may increase the hypoglycemic activities of Insulin Aspart.Investigational, Withdrawn
BumetanideThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Bumetanide.Approved
BuserelinThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Buserelin.Approved
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Insulin Aspart.Approved
Carbaspirin calciumCarbaspirin calcium may increase the hypoglycemic activities of Insulin Aspart.Experimental, Investigational
CarbutamideCarbutamide may increase the hypoglycemic activities of Insulin Aspart.Experimental
CaroxazoneCaroxazone may increase the hypoglycemic activities of Insulin Aspart.Withdrawn
CastanospermineCastanospermine may increase the hypoglycemic activities of Insulin Aspart.Experimental
CeritinibThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Ceritinib.Approved
ChlorothiazideThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorpropamideChlorpropamide may increase the hypoglycemic activities of Insulin Aspart.Approved
ChlorthalidoneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Chlorthalidone.Approved
CiglitazoneCiglitazone may increase the hypoglycemic activities of Insulin Aspart.Experimental
CinoxacinCinoxacin may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the hypoglycemic activities of Insulin Aspart.Approved
ClozapineThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Clozapine.Approved
CorticotropinThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Cortisone acetate.Approved
CyclopenthiazideThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Cyclopenthiazide.Experimental
Cyproterone acetateThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
DabrafenibThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Dabrafenib.Approved
DanazolThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Danazol.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Insulin Aspart.Investigational
DarunavirThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Darunavir.Approved
DeoxyspergualinDeoxyspergualin may increase the hypoglycemic activities of Insulin Aspart.Investigational
dersalazinedersalazine may increase the hypoglycemic activities of Insulin Aspart.Investigational
DesogestrelThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Desogestrel.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Insulin Aspart.Approved
DexamethasoneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Diazoxide.Approved
DienogestThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Dienogest.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Insulin Aspart.Approved
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Insulin Aspart.Illicit
DisopyramideDisopyramide may increase the hypoglycemic activities of Insulin Aspart.Approved
DrospirenoneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Drospirenone.Approved
DulaglutideDulaglutide may increase the hypoglycemic activities of Insulin Aspart.Approved
DuloxetineDuloxetine may increase the hypoglycemic activities of Insulin Aspart.Approved
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Insulin Aspart.Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
EpinephrineThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EscitalopramEscitalopram may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
EstradiolThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Estradiol.Approved, Investigational, Vet Approved
Estrone sulfateThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Etacrynic acid.Approved
Ethinyl EstradiolThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Ethinyl Estradiol.Approved
Ethynodiol diacetateThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Ethynodiol diacetate.Approved
EtonogestrelThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoperidoneEtoperidone may increase the hypoglycemic activities of Insulin Aspart.Withdrawn
EverolimusThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Everolimus.Approved
ExenatideExenatide may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
FleroxacinFleroxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
FludrocortisoneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Fludrocortisone.Approved
FlumequineFlumequine may increase the hypoglycemic activities of Insulin Aspart.Withdrawn
FluoxetineFluoxetine may increase the hypoglycemic activities of Insulin Aspart.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Insulin Aspart.Approved, Illicit
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
FosamprenavirThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Fosamprenavir.Approved
FurazolidoneFurazolidone may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational, Vet Approved
FurosemideThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Furosemide.Approved, Vet Approved
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Insulin Aspart.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
GemifloxacinGemifloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
GlibornurideGlibornuride may increase the hypoglycemic activities of Insulin Aspart.Investigational, Withdrawn
GliclazideGliclazide may increase the hypoglycemic activities of Insulin Aspart.Approved
GlimepirideGlimepiride may increase the hypoglycemic activities of Insulin Aspart.Approved
GlipizideGlipizide may increase the hypoglycemic activities of Insulin Aspart.Approved
GliquidoneGliquidone may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
GLPG-0492GLPG-0492 may increase the hypoglycemic activities of Insulin Aspart.Investigational
GlyburideGlyburide may increase the hypoglycemic activities of Insulin Aspart.Approved
GoserelinThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Goserelin.Approved
GrepafloxacinGrepafloxacin may increase the hypoglycemic activities of Insulin Aspart.Investigational, Withdrawn
GuacetisalGuacetisal may increase the hypoglycemic activities of Insulin Aspart.Experimental
GusperimusGusperimus may increase the hypoglycemic activities of Insulin Aspart.Investigational
HarmalineHarmaline may increase the hypoglycemic activities of Insulin Aspart.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the hypoglycemic activities of Insulin Aspart.Experimental
HistrelinThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Histrelin.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Insulin Aspart.Experimental
HydrochlorothiazideThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
IloperidoneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Iloperidone.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Insulin Aspart.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Indapamide.Approved
IndinavirThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Indinavir.Approved
Insulin DetemirInsulin Aspart may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin GlulisineInsulin Aspart may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanInsulin Human may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Insulin Aspart.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Insulin Aspart.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Insulin Aspart.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Insulin Aspart.Approved
LanreotideInsulin Aspart may increase the hypoglycemic activities of Lanreotide.Approved
LeuprolideThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Leuprolide.Approved, Investigational
LevofloxacinLevofloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Insulin Aspart.Approved
LevonorgestrelThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LinagliptinLinagliptin may increase the hypoglycemic activities of Insulin Aspart.Approved
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Insulin Aspart.Approved, Nutraceutical
LiraglutideLiraglutide may increase the hypoglycemic activities of Insulin Aspart.Approved
LopinavirThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Lopinavir.Approved
LurasidoneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Lurasidone.Approved
MebanazineMebanazine may increase the hypoglycemic activities of Insulin Aspart.Withdrawn
MecaserminMecasermin may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
Medroxyprogesterone acetateThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MesalazineMesalazine may increase the hypoglycemic activities of Insulin Aspart.Approved
MesteroloneMesterolone may increase the hypoglycemic activities of Insulin Aspart.Experimental
MestranolThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Mestranol.Approved
MetforminMetformin may increase the hypoglycemic activities of Insulin Aspart.Approved
MethotrimeprazineThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Methotrimeprazine.Approved
MethyclothiazideThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Methyclothiazide.Approved
Methyl salicylateMethyl salicylate may increase the hypoglycemic activities of Insulin Aspart.Approved, Vet Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
MethylprednisoloneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Insulin Aspart.Approved
MetolazoneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Metolazone.Approved
MifepristoneMifepristone may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
MiglitolMiglitol may increase the hypoglycemic activities of Insulin Aspart.Approved
MiglustatMiglustat may increase the hypoglycemic activities of Insulin Aspart.Approved
MilnacipranMilnacipran may increase the hypoglycemic activities of Insulin Aspart.Approved
MinaprineMinaprine may increase the hypoglycemic activities of Insulin Aspart.Approved
MitiglinideMitiglinide may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
MoclobemideMoclobemide may increase the hypoglycemic activities of Insulin Aspart.Approved
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
NandroloneNandrolone may increase the hypoglycemic activities of Insulin Aspart.Experimental, Investigational
Nandrolone decanoateNandrolone decanoate may increase the hypoglycemic activities of Insulin Aspart.Approved, Illicit
NateglinideNateglinide may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
NefazodoneNefazodone may increase the hypoglycemic activities of Insulin Aspart.Approved, Withdrawn
NelfinavirThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Insulin Aspart.Investigational
NiacinThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NialamideNialamide may increase the hypoglycemic activities of Insulin Aspart.Withdrawn
NilotinibThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Nilotinib.Approved, Investigational
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Insulin Aspart.Investigational
NorethisteroneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
NorgestimateThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Norgestimate.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Insulin Aspart.Withdrawn
OctreotideOctreotide may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
OlanzapineThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Olanzapine.Approved, Investigational
OlsalazineOlsalazine may increase the hypoglycemic activities of Insulin Aspart.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
Oxolinic acidOxolinic acid may increase the hypoglycemic activities of Insulin Aspart.Experimental
OxymetholoneOxymetholone may increase the hypoglycemic activities of Insulin Aspart.Approved, Illicit
PaliperidoneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Paliperidone.Approved
PargylinePargyline may increase the hypoglycemic activities of Insulin Aspart.Approved
ParoxetineParoxetine may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
PasireotideInsulin Aspart may increase the hypoglycemic activities of Pasireotide.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Insulin Aspart.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Insulin Aspart.Approved
PentamidinePentamidine may increase the hypoglycemic activities of Insulin Aspart.Approved
PhenelzinePhenelzine may increase the hypoglycemic activities of Insulin Aspart.Approved
PhenforminPhenformin may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational, Withdrawn
PheniprazinePheniprazine may increase the hypoglycemic activities of Insulin Aspart.Withdrawn
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Insulin Aspart.Withdrawn
PioglitazonePioglitazone may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
Pipemidic acidPipemidic acid may increase the hypoglycemic activities of Insulin Aspart.Experimental
PiperazineThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Pipotiazine.Approved, Investigational
PirlindolePirlindole may increase the hypoglycemic activities of Insulin Aspart.Approved
Piromidic acidPiromidic acid may increase the hypoglycemic activities of Insulin Aspart.Experimental
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Insulin Aspart.Withdrawn
PolythiazideThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Polythiazide.Approved
PramlintidePramlintide may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
PrednisoloneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Prednisone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypoglycemic activities of Insulin Aspart.Approved
ProgesteroneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Progesterone.Approved, Vet Approved
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Insulin Aspart.Investigational
QuetiapineThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Quetiapine.Approved
QuinethazoneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Quinethazone.Approved
QuinineQuinine may increase the hypoglycemic activities of Insulin Aspart.Approved
RasagilineRasagiline may increase the hypoglycemic activities of Insulin Aspart.Approved
RepaglinideRepaglinide may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
RisperidoneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Risperidone.Approved, Investigational
RitonavirThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Ritonavir.Approved, Investigational
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
RosoxacinRosoxacin may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
RufloxacinRufloxacin may increase the hypoglycemic activities of Insulin Aspart.Experimental
SafrazineSafrazine may increase the hypoglycemic activities of Insulin Aspart.Withdrawn
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Insulin Aspart.Approved, Vet Approved
SaquinavirThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Saquinavir.Approved, Investigational
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Insulin Aspart.Approved
SelegilineSelegiline may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational, Vet Approved
SertralineSertraline may increase the hypoglycemic activities of Insulin Aspart.Approved
SirolimusThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Sirolimus.Approved, Investigational
SitafloxacinSitafloxacin may increase the hypoglycemic activities of Insulin Aspart.Experimental, Investigational
SitagliptinSitagliptin may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
SotagliflozinSotagliflozin may increase the hypoglycemic activities of Insulin Aspart.Investigational
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
StanozololStanozolol may increase the hypoglycemic activities of Insulin Aspart.Approved, Vet Approved
SulfadiazineSulfadiazine may increase the hypoglycemic activities of Insulin Aspart.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the hypoglycemic activities of Insulin Aspart.Approved
SulfisoxazoleSulfisoxazole may increase the hypoglycemic activities of Insulin Aspart.Approved, Vet Approved
SulodexideSulodexide may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
SunitinibSunitinib may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
TacrolimusThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Tacrolimus.Approved, Investigational
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Insulin Aspart.Withdrawn
TemsirolimusThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Temsirolimus.Approved
TestosteroneTestosterone may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
Testosterone PropionateTestosterone Propionate may increase the hypoglycemic activities of Insulin Aspart.Approved, Vet Approved
TipranavirThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Tipranavir.Approved, Investigational
TolazamideTolazamide may increase the hypoglycemic activities of Insulin Aspart.Approved
TolbutamideTolbutamide may increase the hypoglycemic activities of Insulin Aspart.Approved
ToloxatoneToloxatone may increase the hypoglycemic activities of Insulin Aspart.Approved
TorasemideThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Torasemide.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Aspart.Experimental
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Insulin Aspart.Approved
TriamcinoloneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TriptorelinThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Triptorelin.Approved, Vet Approved
TroglitazoneTroglitazone may increase the hypoglycemic activities of Insulin Aspart.Investigational, Withdrawn
Trolamine salicylateTrolamine salicylate may increase the hypoglycemic activities of Insulin Aspart.Approved
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational, Withdrawn
VenlafaxineVenlafaxine may increase the hypoglycemic activities of Insulin Aspart.Approved
VildagliptinVildagliptin may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
VogliboseVoglibose may increase the hypoglycemic activities of Insulin Aspart.Approved, Investigational
VorinostatThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Vorinostat.Approved, Investigational
ZimelidineZimelidine may increase the hypoglycemic activities of Insulin Aspart.Withdrawn
ZiprasidoneThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Ziprasidone.Approved
Food Interactions
Not Available

References

Synthesis Reference

Ronald E. Zimmerman, David John Stokell, Michael Patrick Akers, "ASPART PROINSULIN COMPOSITIONS AND METHODS OF PRODUCING ASPART INSULIN ANALOGS THEREFROM." U.S. Patent US20120214963, issued August 23, 2012.

US20120214963
General References
  1. Heller S, Kurtzhals P, Verge D, Lindholm A: Insulin aspart: promising early results borne out in clinical practice. Expert Opin Pharmacother. 2002 Feb;3(2):183-95. [PubMed:11829732]
  2. Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, Vigneri R: Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia. 2010 Aug;53(8):1743-53. doi: 10.1007/s00125-010-1760-6. Epub 2010 Apr 28. [PubMed:20424816]
External Links
KEGG Drug
D04475
PubChem Substance
46507309
ChEMBL
CHEMBL1201496
Therapeutic Targets Database
DAP001092
PharmGKB
PA164784029
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Insulin_aspart
ATC Codes
A10AD06 — Insulin degludec and insulin aspartA10AB05 — Insulin aspartA10AD05 — Insulin aspart
AHFS Codes
  • 68:20.08 — Insulins
FDA label
Download (909 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentDiabetes / Diabetes, Diabetes Mellitus Type 11
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceDiabetes1
1CompletedBasic ScienceDiabetes, Diabetes Mellitus Type 12
1CompletedOtherDiabetes1
1CompletedTreatmentDelivery Systems / Diabetes / Type 2 Diabetes Mellitus2
1CompletedTreatmentDiabetes Mellitus (DM)1
1CompletedTreatmentDiabetes, Diabetes Mellitus Type 14
1CompletedTreatmentDiabetes / Diabetes, Diabetes Mellitus Type 122
1CompletedTreatmentDiabetes / Diabetes, Diabetes Mellitus Type 1 / Healthy Volunteers / Type 2 Diabetes Mellitus1
1CompletedTreatmentDiabetes / Diabetes, Diabetes Mellitus Type 1 / Type 2 Diabetes Mellitus2
1CompletedTreatmentDiabetes / Healthy Volunteers5
1CompletedTreatmentType 2 Diabetes Mellitus1
1RecruitingTreatmentAlzheimer's Disease (AD) / Mild Cognitive Impairment (MCI)1
1RecruitingTreatmentDiabetes / Type 2 Diabetes Mellitus1
1RecruitingTreatmentType1 Diabetes Mellitus2
1, 2CompletedBasic ScienceAlzheimer's Disease (AD)1
1, 2CompletedTreatmentDiabetes Mellitus (DM)1
2CompletedPreventionPost-operative Cognitive Decline / Post-Operative Delirium1
2CompletedTreatmentDiabetes Mellitus (DM)1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 12
2CompletedTreatmentDiabetes / Diabetes, Diabetes Mellitus Type 12
2CompletedTreatmentType 2 Diabetes Mellitus1
2WithdrawnBasic ScienceDiabetes, Diabetes Mellitus Type 11
3Active Not RecruitingTreatmentDiabetes / Type 2 Diabetes Mellitus1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus1
3CompletedPreventionType 2 Diabetes Mellitus1
3CompletedTreatmentDiabetes Type 11
3CompletedTreatmentDiabetes / Diabetes, Diabetes Mellitus Type 128
3CompletedTreatmentDiabetes / Diabetes, Gestational1
3CompletedTreatmentDiabetes / Type 2 Diabetes Mellitus13
3CompletedTreatmentType 2 Diabetes Mellitus4
3RecruitingTreatmentDiabetes1
3RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
3RecruitingTreatmentDiabetes / Diabetes, Diabetes Mellitus Type 11
3RecruitingTreatmentDiabetes / Type 2 Diabetes Mellitus1
3RecruitingTreatmentType 1 Diabetes Mellitus-Type 2 Diabetes Mellitus1
3TerminatedTreatmentAsthma Bronchial / Diabetes / Diabetes, Diabetes Mellitus Type 1 / Type 2 Diabetes Mellitus1
3TerminatedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Diabetes / Diabetes, Diabetes Mellitus Type 1 / Type 2 Diabetes Mellitus1
3TerminatedTreatmentDiabetes / Diabetes, Diabetes Mellitus Type 11
3TerminatedTreatmentDiabetes / Type 2 Diabetes Mellitus2
3TerminatedTreatmentLeukemias / Malignant Lymphomas1
3TerminatedTreatmentType 2 Diabetes Mellitus1
4Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 1 / Nocturnal Hypoglycemia / Recurrent Severe Hypoglycaemia1
4CompletedNot AvailableDiabetes / Diabetes, Diabetes Mellitus Type 1 / Type 2 Diabetes Mellitus1
4CompletedBasic ScienceHyperglycemia, Postprandial / Type 2 Diabetes Mellitus1
4CompletedBasic ScienceKidney Failure,Chronic1
4CompletedDiagnosticDiabetes / Diabetes, Diabetes Mellitus Type 1 / Type 2 Diabetes Mellitus1
4CompletedPreventionCoronary Artery Disease1
4CompletedTreatmentAdmitting Hospital / Diabetes / Non-critically Ill1
4CompletedTreatmentArteriosclerosis / Atherosclerosis / Type 2 Diabetes Mellitus1
4CompletedTreatmentDiabetes2
4CompletedTreatmentDiabetes Mellitus (DM)1
4CompletedTreatmentDiabetes, Diabetes Mellitus Type 19
4CompletedTreatmentDiabetes / Diabetes, Diabetes Mellitus Type 16
4CompletedTreatmentDiabetes / Diabetes, Diabetes Mellitus Type 1 / Type 2 Diabetes Mellitus1
4CompletedTreatmentDiabetes / Type 2 Diabetes Mellitus13
4CompletedTreatmentEvidence of Liver Transplantation / Hyperglycemias / Rejection1
4CompletedTreatmentType 2 Diabetes Mellitus9
4Not Yet RecruitingTreatmentType 2 Diabetes Mellitus1
4RecruitingHealth Services ResearchType 2 Diabetes Mellitus1
4RecruitingPreventionHyperglycemias2
4RecruitingTreatmentAtherosclerosis / Diabetes / Restenosis1
4RecruitingTreatmentDiabetes type11
4RecruitingTreatmentDiabetes, Diabetes Mellitus Type 14
4RecruitingTreatmentDiabetes, Gestational / Neonatal Hypoglycemia1
4RecruitingTreatmentDiabetes / Type 2 Diabetes Mellitus1
4TerminatedTreatmentDiabetes / Diabetes, Diabetes Mellitus Type 11
4TerminatedTreatmentDiabetes / Type 2 Diabetes Mellitus1
4TerminatedTreatmentPost-Transplant Glucocorticoid Induced Diabetes1
4Unknown StatusTreatmentDiabetes, Diabetes Mellitus Type 11
4Unknown StatusTreatmentType 2 Diabetes Mellitus4
4WithdrawnTreatmentDiabetes1
4WithdrawnTreatmentDiabetes, Diabetes Mellitus Type 11
4WithdrawnTreatmentType 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableDelivery Systems / Diabetes / Diabetes, Diabetes Mellitus Type 1 / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableDiabetes / Diabetes, Diabetes Mellitus Type 11
Not AvailableCompletedNot AvailableDiabetes / Diabetes, Diabetes Mellitus Type 1 / Type 2 Diabetes Mellitus10
Not AvailableCompletedNot AvailableDiabetes / Type 2 Diabetes Mellitus7
Not AvailableCompletedBasic ScienceDiabetes1
Not AvailableCompletedBasic ScienceMemory Disorders1
Not AvailableCompletedPreventionDiabetes, Diabetes Mellitus Type 11
Not AvailableCompletedSupportive CareDiabetes1
Not AvailableCompletedSupportive CareDiabetes, Diabetes Mellitus Type 11
Not AvailableCompletedTreatmentCritical Illness1
Not AvailableCompletedTreatmentDiabetes1
Not AvailableCompletedTreatmentDiabetes Mellitus (DM)1
Not AvailableCompletedTreatmentDiabetes, Diabetes Mellitus Type 11
Not AvailableCompletedTreatmentDiabetes / Diabetes, Diabetes Mellitus Type 11
Not AvailableCompletedTreatmentHyperglycemias1
Not AvailableCompletedTreatmentImpaired Glucose Tolerance (IGT) / Macrosomia, Fetal1
Not AvailableCompletedTreatmentKetoacidosis, Diabetic1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus3
Not AvailableCompletedTreatmentType1 Diabetes1
Not AvailableEnrolling by InvitationNot AvailableDiabetes, Gestational1
Not AvailableNot Yet RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
Not AvailableRecruitingOtherType 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentType 2 Diabetes Mellitus1
Not AvailableTerminatedTreatmentDiabetes, Diabetes Mellitus Type 11
Not AvailableUnknown StatusNot AvailableDiabetes, Diabetes Mellitus Type 11
Not AvailableUnknown StatusTreatmentType 2 Diabetes Mellitus1
Not AvailableWithdrawnNot AvailableChronic Kidney Disease (CKD) / Diabetes / Diabetes, Diabetes Mellitus Type 1 / Type 2 Diabetes Mellitus1
Not AvailableWithdrawnSupportive CareDiabetes Mellitus (DM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionSubcutaneous100 [iU]/mL
Injection, solutionIntravenous; Subcutaneous100 [iU]/mL
Injection, suspensionSubcutaneous100 [iU]/mL
Injection, suspensionSubcutaneous100 U/ml
Injection, solutionIntravenous; Subcutaneous100 U/ml
SolutionSubcutaneous100 unit
Injection, solutionSubcutaneous
Prices
Unit descriptionCostUnit
Novolog 100 unit/ml cartridge14.81USD ml
Novolog mix 70-30 cartridge10.45USD ml
Novorapid 100 unit/ml Cartridge3.89USD cartridge
Novorapid 100 unit/ml2.92USD cartridge
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5618913No1994-06-072014-06-07Us
US8672898No2002-01-022022-01-02Us
US8684969No2005-10-202025-10-20Us
US9132239No2012-02-012032-02-01Us
US8920383No2006-07-172026-07-17Us
US7686786No2006-08-032026-08-03Us
US6899699No2002-01-022022-01-02Us
US5866538Yes1997-12-202017-12-20Us
US9108002No2006-01-202026-01-20Us
USRE41956Yes2001-07-212021-07-21Us
US9265893No2012-09-232032-09-23Us
US6004297Yes1999-07-282019-07-28Us
USRE43834No1999-01-282019-01-28Us
US7615532No2005-05-252025-05-25Us
US9486588No2002-01-022022-01-02Us
US9457154No2007-09-272027-09-27Us
USRE46363No2006-08-032026-08-03Us
US9687611No2007-02-272027-02-27Us

Properties

State
Liquid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Receptor signaling protein tyrosine kinase activity
Specific Function
Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (...
Gene Name
INSR
Uniprot ID
P06213
Uniprot Name
Insulin receptor
Molecular Weight
156331.465 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Zib I, Raskin P: Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab. 2006 Nov;8(6):611-20. [PubMed:17026485]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on June 30, 2007 08:44 / Updated on November 19, 2017 20:34